Nuclastaml Injection 1 ml belongs to a group of medicines called RANK ligand inhibitors used to treat osteoporosis in postmenopausal women and men who have an increased risk of fracture. Nuclastaml Injection 1 ml is also used to treat bone loss due to reduced testosterone level caused by surgery, due to the treatment with medicines such as glucocorticoids and in patients with prostate cancer. Nuclastaml Injection 1 ml may also be used to reduce the risk of fractures in people with multiple myeloma, giant cell tumour of the bone, and to treat high calcium levels caused due to cancer.
 
Nuclastaml Injection 1 ml contains ‘denosumab’, which works by blocking a receptor in the body that causes bone loss, thereby treats bone loss. Nuclastaml Injection 1 ml treats giant cell tumour of bone (GCTB) by blocking certain receptors in the tumour cells, thereby slowing the tumour growth. Nuclastaml Injection 1 ml helps treat high calcium levels by decreasing bone breakdown as a breakdown of the bones releases calcium. Nuclastaml Injection 1 ml makes the bones stronger and less likely to break.
 
Nuclastaml Injection 1 ml will be administered by a healthcare professional; do not self-administer. In some cases, you may experience common side-effects such as bone/joint/muscle pain, arm/leg pain, abdominal discomfort, constipation, and painful/frequent urination. You are advised to talk to your doctor if the side effects persist or worsen.
 
Nuclastaml Injection 1 ml might cause osteonecrosis of the jaw; therefore, maintain good dental hygiene and receive regular dental check-ups whilst on treatment with Nuclastaml Injection 1 ml. Avoid taking Nuclastaml Injection 1 ml if you are pregnant. Consult your doctor before taking Nuclastaml Injection 1 ml if you are breastfeeding. Nuclastaml Injection 1 ml is not recommended for children below 18 years as safety and effectiveness have not been established. Keep your doctor informed about your health condition and medicines to rule out any interactions.

Nuclastaml Injection 1 ml belongs to a group of medicines called RANK ligand inhibitors used to treat osteoporosis in postmenopausal women and men who have an increased risk of fracture. Nuclastaml Injection 1 ml is also used to treat bone loss due to reduced hormone levels caused by surgery or due to treatment with medicines in patients with prostate cancer. It is also used to treat bone loss occurring due to long-term treatment with glucocorticoids in patients who are at an increased risk of fractures. Nuclastaml Injection 1 ml may also be used to reduce the risk of fractures in people with multiple myeloma, giant cell tumours of the bone and to treat high calcium levels caused due to cancer. Nuclastaml Injection 1 ml binds to a protein on RANK ligand on osteoclast (cells that cause bone breakdown) and inhibits their formation, functioning and survival. Thereby decreases bone breakdown, increases bone density, and strengthens the bone. Nuclastaml Injection 1 ml treats giant cell tumour of bone (GCTB) by blocking certain receptors in the tumour cells, thereby slows the tumour growth. Nuclastaml Injection 1 ml helps treat high calcium levels by decreasing bone breakdown as the breakdown of the bones releases calcium. Nuclastaml Injection 1 ml makes the bones stronger and less likely to break.

• Bone/joint/muscle pain
• Pain in extremities (arm/leg pain)
• Abdominal discomfort
• Constipation
• Painful/frequent urination
• Upper respiratory tract infection
• Rash
• Eczema
• Hair loss

Do not take Nuclastaml Injection 1 ml if you are allergic to any of its components; if you have hypocalcaemia (low levels of calcium in the blood). Inform your doctor if you have low levels of calcium, kidney dysfunction, liver problems, poor dental health, gum problems, weak immune system, hypoparathyroidism (decreased function of the parathyroid gland), malabsorption, latex allergy, undergone thyroid surgery, planned dental procedure, if you are taking glucocorticoids, or cannot take calcium and vitamin D supplements. Avoid taking Nuclastaml Injection 1 ml if you are pregnant. Consult your doctor if you are breastfeeding. Nuclastaml Injection 1 ml is not recommended for children below 18 years as safety and effectiveness have not been established.

Drug-Drug Interactions: Nuclastaml Injection 1 ml may interact with kinase inhibitors (palbociclib).

Drug-Food Interactions: No interactions found/established.

Drug-Disease Interactions: Inform your doctor if you have hypocalcaemia (low levels of calcium in the blood) or immunosuppression.

• PALBOCICLIB

• Include dairy products like milk, yoghurt, cheese, or milk-based custard in your diet.
• Eat daily a serving of broccoli, cabbage, bok choy (Chinese white cabbage), spinach, and other green leafy vegetables.
• Snack on calcium-rich nuts like Brazil nuts or almonds.
• Sprinkle sesame seeds over your food, vegetables, and salads. Sesame seeds are high in calcium.
• Avoid or reduce the intake of caffeine, soft drinks, and alcohol as they may inhibit calcium absorption.
• Replace the meat with tofu or tempeh for extra calcium in your food.

• If you are a woman of child-bearing potential, use effective contraception during the treatment with Nuclastaml Injection 1 ml and for 5 months after discontinuation. 
• Your doctor might prescribe calcium and vitamin D supplements whilst on treatment with Nuclastaml Injection 1 ml.

Osteoporosis: It is a bone disease that weakens and thins the bones by decreasing bone density. As the density of bones decreases, they weaken and are more likely to break. Postmenopausal women are more likely to develop osteoporosis than men because, at menopause, women’s ovaries stop producing oestrogen (a female hormone) that is essential to keep bones healthy. Following menopause, bone loss occurs, making bones weak and more likely to break. Osteoporosis can also occur in men due to ageing and/or low levels of testosterone hormone. Signs and symptoms include back pain caused by a fractured or collapsed vertebra, loss of height over time, a stooped posture, bones that break much more easily than expected.